Oncode Institute today announced that its Supervisory Board has appointed Chris De Jonghe as Valorization Director. Chris will start at Oncode Institute on May 4thand assumes her role as Valorization Director and all responsibilities on June 1st. Angus Livingstone, Oncode’s founding Valorization Director will stay with Oncode Institute until May 31st.
Chris has a wealth of multi-disciplinary experience in the life sciences sector. She currently holds the position of Group Manager Venture Capital and Head of Life Sciences & Care at PMV (Participatie Maatschappij Vlaanderen) in Brussels, where she is a member of its Management Committee. PMV is a government-backed investment company holding over 1 billion euro assets under management. Previously, Chris worked for more than 10 years at the tech transfer team of VIB (Vlaams Instituut voor Biotechnologie), where she was involved in research collaborations, IP-licensing and new venture creation. Chris is a biochemist by training and obtained her PhD in the field of neurodegeneration. In addition, she holds a law degree. She is a board member in several operational life sciences companies, investment funds and cluster organizations.
Angus Livingstone says: “I am delighted that Chris will be succeeding me as Oncode’s Valorization Director. She brings a wealth of experience and an outstanding network to the role. Oncode will be in good hands with Chris at the helm.”
Chris De Jonghe says: “I feel honoured to become part of this exceptional organization, strongly supported by a unique public-private partnership. Translating breakthrough science into innovative treatments for the benefit of patients has always been the driving force throughout my career. Succeeding Angus will be a challenging task: not only did he found Oncode, he also assembled a highly skilled team and established Oncode as an outstanding professional organization. I look forward to contributing to Oncode’s further development as a leading oncology research institute. I will use all of my expertise and energy to focus on the one thing that ultimately really matters: improving the life of cancer patients.”
Angus Livingstone concludes: “I originally came to the Netherlands in April 2016 to found Onco XL – now Oncode Institute. The opportunity to create a new institute with embedded valorization was too good to miss. I am proud of what we have achieved in our first two years of operation and the solid foundation that has been laid for the future: outsmarting cancer, impacting lives.”
